Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291.
McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, Navia BA, Schifitto G, Katzenstein D, Rask C, Zaborski L, Smith ME, Shriver S, Millar L, Clifford DB, Karalnik IJ. McArthur JC, et al. Among authors: katzenstein d. Neurology. 2000 Mar 14;54(5):1080-8. doi: 10.1212/wnl.54.5.1080. Neurology. 2000. PMID: 10720278 Clinical Trial.
Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.
Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC; AIDS Clinical Trials Group Team 291. Schifitto G, et al. Among authors: katzenstein d. Neurology. 2001 Oct 9;57(7):1313-6. doi: 10.1212/wnl.57.7.1313. Neurology. 2001. PMID: 11591856 Clinical Trial.
Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy.
Polydefkis M, Yiannoutsos CT, Cohen BA, Hollander H, Schifitto G, Clifford DB, Simpson DM, Katzenstein D, Shriver S, Hauer P, Brown A, Haidich AB, Moo L, McArthur JC. Polydefkis M, et al. Among authors: katzenstein d. Neurology. 2002 Jan 8;58(1):115-9. doi: 10.1212/wnl.58.1.115. Neurology. 2002. PMID: 11781415
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra CM, Kolson D, Weihe J, Remmel R, Katzenstein D, Clifford DB; ACTG A5090 Team. Schifitto G, et al. Among authors: katzenstein d. Neurology. 2007 Sep 25;69(13):1314-21. doi: 10.1212/01.wnl.0000268487.78753.0f. Epub 2007 Jul 25. Neurology. 2007. PMID: 17652642 Clinical Trial.
Plasma carnitine in HIV-associated neuropathy.
Simpson DM, Katzenstein D, Haidich B, Millington D, Yiannoutsos C, Schifitto G, McArthur J; AIDS Clinical Trials Group Protocol 291/860 Study Team. Simpson DM, et al. Among authors: katzenstein d. AIDS. 2001 Nov 9;15(16):2207-8. doi: 10.1097/00002030-200111090-00025. AIDS. 2001. PMID: 11684949 Clinical Trial. No abstract available.
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, Hammer SM, Cotton DJ. Currier JS, et al. Among authors: katzenstein da. J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):316-24. doi: 10.1097/00126334-200008010-00003. J Acquir Immune Defic Syndr. 2000. PMID: 11015147 Clinical Trial.
Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
Katzenstein DA, Hughes M, Albrecht M, Hammer S, Para M, Murphy R, Valdez H, Haubrich R, Liou S. Katzenstein DA, et al. AIDS Res Hum Retroviruses. 2000 Jul 20;16(11):1031-7. doi: 10.1089/08892220050075282. AIDS Res Hum Retroviruses. 2000. PMID: 10933617 Clinical Trial.
312 results